文献速递呼吸道感染呼吸危重症与机械通气

病毒性下呼吸道感染住院的临床结局与费用

Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations
RSS 订阅 · BMJ Open Respiratory Research

各病毒病因均造成沉重负担,2020-2021年达峰,再入院和费用至2022-2023年仍高。

要点

  • 38.1%的病毒性下呼吸道感染住院患者在30天内入住ICU。
  • 30天死亡率为15.1%,NIV和IMV/ECMO使用率分别为8.4%和8.7%。

核心结论

  • 所有病毒病因的严重病毒性下呼吸道感染均给美国医疗系统带来沉重负担,即使非大流行年份也频繁入住ICU和使用通气,相关费用可观。

主要发现

  • 8.4%和8.7%分别在索引后30天内接受NIV和IMV/ECMO,30天死亡率为15.1%。
  • 所有病毒病因的ICU入住、死亡率和费用均较高,2020-2021年达峰;再入院和费用至2022-2023年仍高。

临床怎么用

  • 临床应认识到病毒性下呼吸道感染住院患者ICU入住和死亡风险较高,需早期评估病情严重程度。
  • 即使非大流行年份,病毒性下呼吸道感染仍带来高再入院率和费用,出院后管理应关注再入院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background An updated comprehensive assessment of the burden of hospitalised viral lower respiratory tract disease (LRTD) is especially salient after the COVID-19 pandemic. Therefore, we aimed to comprehensively describe clinical characteristics and outcomes of US adults hospitalised with viral LRTD between 2015 and 2023. Methods In this retrospective analysis, adults hospitalised between 1 January 2015 and 31 March 2023 were identified using Optum’s deidentified Clinformatics Data Mart Database. Index date was the first International Classification of Diseases, 9th/10th Revision (ICD-9/10) code for viral LRTD hospitalisation. Outcomes included intensive care unit (ICU) admission, non-invasive ventilation (NIV), invasive mechanical ventilation/extracorporeal membrane oxygenation (IMV/ECMO), costs, 30-day mortality and 30-day readmissions. Outcomes were stratified by viral aetiology ( ICD-9/10 ), clinical severity and time period (2015–2019; 2020–2021; 2022–2023). Time-to-event data were assessed using Kaplan-Meier estimates. Results Of 387 449 patients hospitalised for viral LRTD, 38.1% were admitted to ICU within 30 days of index (84.6% of these were admitted on index date); 8.4% and 8.7%, respectively, received NIV and IMV/ECMO within 30 days of index and 30-day mortality was 15.1%. Median (IQR) length of stay and mean (SD) hospitalisation costs were 7 (4–15) days and $42 752 ($44 841), respectively. Admission to ICU, mortality and costs were substantial across all aetiologies but peaked from 2020 to 2021; readmissions and costs remained high even into 2022–2023. Conclusions Severe viral LRTD incurred substantial burden for US healthcare systems across all viral aetiologies, even in non-pandemic years, with frequent ICU admission and ventilation use, and with considerable associated costs. Readmission rates and costs remain high even after the peak of COVID-19.

来源:BMJ Open Respiratory Research,查看原文。版权归原作者所有。

引用

  1. BMJ Open Respiratory Research:Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。